Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kura Oncology and keeping the price target at $40.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily focusing on the promising clinical data presented by Kura Oncology at ESMO 2025. The company showcased preliminary results from three Phase 1 trials involving its farnesyl transferase inhibitor (FTI) candidates, darlifarnib and tipifarnib, which are being tested for the treatment of various solid tumors.
These early clinical results are significant as they build on previous preclinical studies, demonstrating the potential of these FTIs as effective combination partners with major precision medicines. The trials revealed enhanced antitumor activity in molecularly selected solid tumor patients, a group that is typically difficult to treat with existing therapies. The results from the monotherapy and combination studies, particularly in renal cell carcinoma, highlight the potential of darlifarnib as a next-generation treatment option, supporting the Buy rating.
In another report released on October 18, LifeSci Capital also maintained a Buy rating on the stock with a $24.00 price target.